Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Yamaha Enters Medical Field with Cell Handler, a Device to Support Drug Discovery
September 4, 2017
- Mirogabalin Delivers Positive Data for Diabetic Peripheral Neuropathic Pain: Daiichi Sankyo
September 1, 2017
- Daiichi Sankyo Ditches CL-108 Deal, Takes 27.8 Billion Yen Impaired Loss
September 1, 2017
- Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
- Opdivo Clinches Batch of New Indications in South Korea
August 31, 2017
- Praluent Self-Injection Possible from Sept. 1; Repatha Auto Mini Doser Approved
August 31, 2017
- Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
- Trerief Filed for Parkinsonism in DLB: Sumitomo Dainippon
August 31, 2017
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
- Daiichi Sankyo’s DS-8201 Gets Breakthrough Therapy Designation
August 31, 2017
- Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
- Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
August 30, 2017
- Boston Pharma Gets Rights to Daiichi Sankyo’s Preclinical RET Inhibitor
August 30, 2017
- BMS, Daiichi Sankyo to Collaborate on Opdivo-DS-8201 Combo
August 30, 2017
- Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
- Takeda Divesting Laboratory Animal Unit amid R&D Realignment Drive
August 29, 2017
- Suzuken Group to Shed 350 Jobs as It Seeks SGA Efficiency
August 29, 2017
- FGF23 Antibody Burosumab Filed in US: Kyowa Kirin, Ultragenyx
August 28, 2017
- Poteligeo Earns FDA’s BT Designation for CTCL: Kyowa Kirin
August 28, 2017
- Spinraza to Hit Japan Market on August 30
August 28, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…